Antibodies are a mainstay as therapeutics, with emerging formats, combinations and innovative delivery methodologies promising to expand their reach across disease indications. This meeting will showcase trailblazing approaches in the design and engineering of novel biologic modalities as linked to their pre-clinical development and selected early outcomes in the clinic.

Specifically, the topics covered will engage discussions around:

1) antibody-based protein degraders,
2) next-generation antibody drug conjugate technologies
3) precision biologics
4) increasing accessibility of antibody drugs on a global scale
5) advances in combination biology and modalities
6) Fc domain engineering

In addition, two workshops will stimulate discussions around 1) an evolving landscape of regulatory considerations for new biologics, and 2) artificial-intelligence and machine-learning. These topics will draw from examples across medical indications, ranging from cancer to infectious diseases to autoimmune diseases and diseases of the central nervous system. Thus, this meeting will engage a vast audience, bring different arenas together within the antibody as drugs community and allow the field as a whole to challenge current paradigms and establish new research directions.

This conference is co-located with the Keystone Symposium on Drug Delivery to the Brain: Emerging Modalities to encourage cross-disciplinary insights and collaborations towards novel treatment modalities for brain diseases.

Meeting organizers Dr. Jean-Philippe Julien and Dr. Katherine Harris talk about why you should attend this meeting in the video below: